This article was originally published in The Gray Sheet
Settlement pact resolves all outstanding disputes between the firm and Meso Scale Diagnostics (MSD) - a joint venture between BioVeris and Meso Scale Technologies (MST) - as well as with MST CEO Jacob Wohlstadter. The deal includes a $5 mil. payment to MSD and an agreement for MSD or MST to purchase BioVeris' interest in MSD. BioVeris also gained sales data on the joint venture needed to file financial statements. The firm's delay in filing a 10-K for fiscal 2004 (ended March 31) with the SEC led to a July Nasdaq delisting notice (1"The Gray Sheet" July 26, 2004, p. 11)...
You may also be interested in...
BioVeris will file a request by August for a Nasdaq Listing Qualifications Panel to review a staff determination and stay the firm's stock delistment
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.